News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
517,157 Results
Type
Article (33321)
Company Profile (55)
Press Release (483779)
Multimedia
Podcasts (129)
Webinars (17)
Section
Business (147782)
Career Advice (1793)
Deals (24880)
Drug Delivery (90)
Drug Development (62159)
Employer Resources (116)
FDA (12141)
Job Trends (10843)
News (251165)
Policy (23526)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (2219)
Academic (1)
Accelerated approval (31)
Adcomms (22)
Allergies (123)
Alliances (39617)
ALS (166)
Alzheimer's disease (1541)
Antibody-drug conjugate (ADC) (276)
Approvals (12452)
Artificial intelligence (501)
Autoimmune disease (183)
Automation (41)
Bankruptcy (233)
Best Places to Work (8933)
BIOSECURE Act (8)
Biosimilars (138)
Biotechnology (42)
Bladder cancer (158)
Brain cancer (50)
Breast cancer (558)
Cancer (4351)
Cardiovascular disease (394)
Career advice (1528)
Career pathing (38)
CAR-T (222)
CDC (40)
Celiac Disease (1)
Cell therapy (637)
Cervical cancer (32)
Clinical research (53714)
Collaboration (1616)
Company closure (3)
Compensation (591)
Complete response letters (54)
COVID-19 (1972)
CRISPR (84)
C-suite (685)
Cystic fibrosis (117)
Data (6181)
Decentralized trials (3)
Denatured (43)
Depression (125)
Dermatology (46)
Diabetes (480)
Diagnostics (5021)
Digital health (39)
Diversity (7)
Diversity, equity & inclusion (38)
Drug discovery (241)
Drug pricing (125)
Drug shortages (25)
Duchenne muscular dystrophy (239)
Earnings (67470)
Editorial (49)
Employer branding (14)
Employer resources (102)
Events (78951)
Executive appointments (762)
FDA (14945)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (12)
Frontotemporal dementia (27)
Funding (1189)
Gene editing (172)
Generative AI (51)
Gene therapy (603)
GLP-1 (839)
Government (3501)
Grass and pollen (6)
Guidances (365)
Healthcare (14362)
HIV (62)
Huntington's disease (42)
IgA nephropathy (80)
Immunology and inflammation (182)
Immuno-oncology (65)
Indications (136)
Infectious disease (2218)
Inflammatory bowel disease (161)
Inflation Reduction Act (12)
Influenza (95)
Intellectual property (224)
Interviews (317)
IPO (12483)
IRA (33)
Job creations (2204)
Job search strategy (1260)
JPM (52)
Kidney cancer (15)
Labor market (57)
Layoffs (339)
Leadership (34)
Legal (5604)
Liver cancer (69)
Longevity (19)
Lung cancer (577)
Lymphoma (356)
Machine learning (38)
Management (38)
Manufacturing (661)
MASH (192)
Medical device (9835)
Medtech (9900)
Mergers & acquisitions (13388)
Metabolic disorders (1213)
mRNA (122)
Multiple sclerosis (136)
NASH (21)
Neurodegenerative disease (319)
Neuropsychiatric disorders (73)
Neuroscience (2683)
Neurotech (1)
NextGen: Class of 2026 (4805)
Non-profit (3619)
Now hiring (61)
Obesity (529)
Opinion (241)
Ovarian cancer (129)
Pain (202)
Pancreatic cancer (199)
Parkinson's disease (281)
Partnered (28)
Patents (426)
Patient recruitment (464)
Peanut (42)
People (39850)
Pharmaceutical (12)
Pharmacy benefit managers (22)
Phase 1 (16277)
Phase 2 (23643)
Phase 3 (18172)
Pipeline (6156)
Policy (211)
Postmarket research (2201)
Preclinical (7374)
Press Release (41)
Prostate cancer (249)
Psychedelics (36)
Radiopharmaceuticals (253)
Rare diseases (825)
Real estate (3381)
Recruiting (43)
Regulatory (18259)
Reports (32)
Research institute (1896)
Resumes & cover letters (279)
Rett syndrome (29)
RNA editing (14)
RSV (73)
Schizophrenia (146)
Series A (198)
Series B (135)
Service/supplier (4)
Sickle cell disease (89)
Special edition (14)
Spinal muscular atrophy (118)
Sponsored (34)
Startups (2305)
State (1)
Stomach cancer (11)
Supply chain (76)
Tariffs (41)
The Weekly (84)
Vaccines (791)
Venture capital (60)
Weight loss (325)
Women's health (77)
Worklife (16)
Date
Today (133)
Last 7 days (587)
Last 30 days (2298)
Last 365 days (23838)
2026 (6336)
2025 (23907)
2024 (26869)
2023 (30154)
2022 (38013)
2021 (41136)
2020 (39963)
2019 (34544)
2018 (26019)
2017 (24145)
2016 (23286)
2015 (27347)
2014 (21917)
2013 (18668)
2012 (19081)
2011 (18739)
2010 (17550)
Location
Africa (644)
Alabama (71)
Alaska (4)
Arizona (198)
Arkansas (8)
Asia (28861)
Australia (5100)
California (9300)
Canada (2665)
China (944)
Colorado (406)
Connecticut (430)
Delaware (284)
Europe (66875)
Florida (1475)
Georgia (334)
Hawaii (1)
Idaho (37)
Illinois (734)
India (64)
Indiana (477)
Iowa (13)
Japan (398)
Kansas (100)
Kentucky (26)
Louisiana (28)
Maine (73)
Maryland (1160)
Massachusetts (6553)
Michigan (283)
Minnesota (454)
Mississippi (6)
Missouri (88)
Montana (21)
Nebraska (20)
Nevada (109)
New Hampshire (62)
New Jersey (2781)
New Mexico (17)
New York (2633)
North Carolina (1253)
North Dakota (6)
Northern California (4538)
Ohio (283)
Oklahoma (16)
Oregon (29)
Pennsylvania (1975)
Puerto Rico (12)
Rhode Island (32)
South America (896)
South Carolina (45)
South Dakota (1)
Southern California (3779)
Tennessee (170)
Texas (1546)
United States (33751)
Utah (297)
Vermont (1)
Virginia (237)
Washington D.C. (62)
Washington State (802)
West Virginia (2)
Wisconsin (86)
Wyoming (2)
517,157 Results for "crg and associates llc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Genetown
T2 Biosystems Announces CRG’s Conversion from Preferred Stock to Common Stock - May 14, 2024
T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced that entities affiliated with CRG Servicing LLC have converted Series A and Series B Convertible Preferred Stock to Common Stock.
May 14, 2024
·
4 min read
Genetown
T2 Biosystems Announces Agreement with CRG for the Conversion of $15 Million of CRG Term Loan into Equity
T2 Biosystems, Inc. announced the entrance into a definitive agreement to convert $15 million of its term loan with entities affiliated with CRG Servicing LLC into T2 Biosystems equity upon stockholder approval.
February 15, 2024
·
5 min read
Press Releases
Aethlon Medical Engages Maxim Group LLC to Evaluate Strategic Opportunities
March 12, 2026
·
5 min read
Press Releases
LENSAR® Announces Termination of Merger Agreement with Alcon Research, LLC
March 16, 2026
·
5 min read
Press Releases
CollectiveMinds LLC Places Robert Hollingsworth, PhD as Chief Scientific Officer of Protillion Biosciences
April 1, 2026
·
4 min read
Genetown
T2 Biosystems Announces the Conversion of an Additional $15 Million of CRG Term Loan into Equity
T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced the conversion of an additional $15 million of its term loan with entities affiliated with CRG Servicing LLC into T2 Biosystems equity.
May 6, 2024
·
4 min read
Press Releases
ITF Therapeutics LLC Announces Multiple Data Presentations at 2026 MDA Clinical and Scientific Conference
February 23, 2026
·
9 min read
Press Releases
Alembic Therapeutics LLC Announces the Launch of PIVYA® (pivmecillinam)
February 18, 2026
·
2 min read
Press Releases
ITF Therapeutics LLC Presents New Data and Analyses on Givinostat for Treatment of Duchenne Muscular Dystrophy at 2026 MDA Clinical and Scientific Conference
March 9, 2026
·
9 min read
Biotech Bay
Avinger Announces Conversion of $11 Million of CRG Debt into Preferred Equity
Avinger, Inc. announced the conversion of $11 million or approximately 80% of its existing debt with entities affiliated with CRG Partners III L.P. into a shares of a new series of convertible preferred stock.
May 16, 2024
·
3 min read
1 of 51,716
Next
